N
VRTX icon

Natixis’s Vertex Pharmaceuticals VRTX Stock Holding History

Natixis’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,000
Closed -$11.6M – 1180
2025
Q1 		$11.6M Buy
+24,000
New +$11.2M 0.06% 207

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Natixis's VRTX Position: Q1 2026 in Review

Natixis reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, selling an estimated $5.61M and leaving 48,192 shares worth $21.5M. The position accounts for 0.08% of the portfolio, ranked #181.

Natixis first reported a position in VRTX in Q2 2013 and has held it in 42 quarters since. The position peaked at $73.1M in Q4 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Natixis held 48,192 shares of Vertex Pharmaceuticals worth $21.5M as of Q1 2026.
  • Natixis sold 12,026 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.61M.
  • Vertex Pharmaceuticals made up 0.08% of Natixis's portfolio in Q1 2026, its #181 holding.
  • Natixis first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Natixis's Vertex Pharmaceuticals position peaked at $73.1M in Q4 2017.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.